Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Abizer Gaslightwala
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- 1.43
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -12.88
Financials
Net Income
$-4.81MEBITDA
$-4.73MFree Cash Flow
$-3.11MEPS (diluted)
$-272.00Shares Outstanding (diluted)
1.79M+609242.9%Operating Expenses
$4.60MCash & Debt
$7.69MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-17.30M | $-20800.00 |
| 2024 | $0.00 | $-19.79M | $-132800.00 |
| 2023 | $0.00 | $-10.01M | $-163200.00 |
| 2022 | $0.00 | $-17.75M | $-455200.00 |
| 2021 | $0.00 | $-17.42M | $-649600.00 |
| 2020 | $0.00 | $-17.08M | $-896000.00 |
| 2019 | $0.00 | $-16.85M | $-1472000.00 |
| 2018 | $0.00 | $-19.95M | $-2129600.00 |
| 2017 | $0.00 | $-27.92M | $-4540800.00 |
| 2016 | $0.00 | $-18.14M | $-2464800.00 |
| 2015 | $0.00 | $-45.32M | $-8509600.00 |
| 2014 | $0.00 | $-9.65M | $-3644000.00 |
| 2013 | $0.00 | $-3.62M | $-2431200.00 |
| 2012 | $0.00 | $-1.44M | $-48.00 |
Valuation
AKTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·40d ago·Neutral
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference Video webcast now available here
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027
View source ↗
Earnings
Fri, Dec 4(in 8 weeks)
Consensus estimate $-2.23 per share
Typical surprise -108.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-272.00 vs $-1.04miss
- Tue, May 19$-9.74 vs $-1.33miss
- Mon, Mar 30$-2.99 vs $-1.80miss
- Thu, Nov 13$-4.00 vs $-1.60miss
- Wed, Aug 13$-2.40 vs $-3.60beat
- Wed, Apr 16$-6.80 vs $-40.00beat
Estimates and results for AKTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AKTX officers and directors.
- Bought
- $2.9m
- Sold
- —
37 trades
0 trades
- Neal James Rbought
- Neal James Rbought
- Neal James Rbought
- Neal James Rbought
- Prudo-chlebosz Raymondbought
- Prudo-chlebosz Raymondbought
- Prudo-chlebosz Raymondbought
- Prudo-chlebosz Raymondbought
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AKTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.